Tumor-Stromal Interactions Influence Radiation Sensitivity in Epithelial- versus Mesenchymal-Like Prostate Cancer Cells.
HS-27a human bone stromal cells, in 2D or 3D coultures, induced cellular plasticity in human prostate cancer ARCaP(E) and ARCaP(M) cells in an EMT model. Cocultured ARCaP(E) or ARCaP(M) cells with HS-27a, developed increased colony forming capacity and growth advantage, with ARCaP(E) exhibiting the most significant increases in presence of bone or prostate stroma cells. Prostate (Pt-N or Pt-C) or bone (HS-27a) stromal cells induced significant resistance to radiation treatment in ARCaP(E) cells compared to ARCaP(M) cells. However pretreatment with anti-E-cadherin antibody (SHEP8-7) or anti-alpha v integrin blocking antibody (CNT095) significantly decreased stromal cell-induced radiation resistance in both ARCaP(E)- and ARCaP(M)-cocultured cells. Taken together the data suggest that mesenchymal-like cancer cells reverting to epithelial-like cells in the bone microenvironment through interaction with bone marrow stromal cells and reexpress E-cadherin. These cell adhesion molecules such as E-cadherin and integrin alpha v in cancer cells induce cell survival signals and mediate resistance to cancer treatments such as radiation.
Josson
Sajni
S
Department of Urology, Emory School of Medicine, Atlanta, GA 30311, USA.
Sharp
Starlette
S
Sung
Shian-Ying
SY
Johnstone
Peter A S
PA
Aneja
Ritu
R
Wang
Ruoxiang
R
Gururajan
Murali
M
Turner
Timothy
T
Chung
Leland W K
LW
Yates
Clayton
C
Br J Cancer. 2007 Apr 23;96(8):1246-52
17406365
Oncogene. 2001 Mar 22;20(12):1525-8
11313896
Prostate. 2010 Apr 1;70(5):518-28
19918799
Surgery. 2002 Aug;132(2):141-8
12219004
J Clin Invest. 2002 Apr;109(7):857-62
11927611
Eur J Pharmacol. 2008 Jun 24;588(1):1-8
18448095
J Cell Sci. 2010 Jan 15;123(Pt 2):266-76
20048343
Prostate. 2008 Nov 1;68(15):1681-8
18712716
Anticancer Res. 2007 Nov-Dec;27(6B):3903-8
18225549
Lab Invest. 2003 Mar;83(3):435-48
12649344
Cancer Biol Ther. 2005 Apr;4(4):365-70
15846061
Clin Exp Metastasis. 2008;25(6):601-10
18535913
Prostate. 2006 Nov 1;66(15):1664-73
16902972
J Biol Chem. 2001 Jul 6;276(27):24661-6
11323412
Curr Opin Genet Dev. 2005 Feb;15(1):97-101
15661539
J Biol Chem. 2003 Jan 17;278(3):1824-30
12435727
Cancer Res. 2001 May 1;61(9):3819-25
11325858
Cancer Res. 2004 Sep 1;64(17):6327-36
15342422
Int J Dev Biol. 2000 Apr;44(3):297-307
10853826
Cell Res. 2008 Aug;18(8):858-70
18645583
Cancer Res. 2006 Dec 1;66(23):11271-8
17145872
Dev Cell. 2001 Jul;1(1):37-49
11703922
Nat Rev Cancer. 2002 Jun;2(6):442-54
12189386
Clin Exp Metastasis. 2008;25(6):621-8
18600305
Prostate. 2008 Jan 1;68(1):92-104
18008334
Cancer. 2000 Jun 15;88(12 Suppl):2995-3001
10898343
Cancer Res. 2002 Dec 1;62(23):6891-900
12460904
Crit Rev Oncol Hematol. 2002 Jan;41(1):11-28
11796229
J Biol Chem. 2003 Dec 12;278(50):50402-11
14523021
EMBO J. 2004 Apr 21;23(8):1739-48
15057284
Hum Pathol. 2001 Jul;32(7):690-7
11486167
Nat Rev Cancer. 2002 Aug;2(8):563-72
12154349
Semin Cancer Biol. 2002 Oct;12(5):373-9
12191636
J Cell Sci. 1995 May;108 ( Pt 5):1945-57
7544798
Adv Cancer Res. 2007;97:225-46
17419948
Mol Ther. 2005 Oct;12(4):634-43
16039164
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10356-61
11526241
Cancer Res. 2008 Dec 1;68(23):9996-10003
19047182
Cancer Sci. 2006 Feb;97(2):155-62
16441427
Radiat Res. 2009 Sep;172(3):306-13
19708779